Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: The role of the pathoantigenic HISA70 DNA vaccine

Veterinary Research

Volumn 43, Issue 1, 2012, Pages

  Domínguez Bernal, Gustavo ^a   Horcajo, Pilar ^a   Orden, José A ^a   De La Fuente, Ricardo ^a   Herrero Gil, Aldara ^a   Ordóñez Gutiérrez, Lara ^b   Carrión, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; EUKARYOTA; LEISHMANIA MAJOR; MURINAE; MUS;

CYTOKINE; DNA VACCINE; LEISHMANIA VACCINE; POLYPROTEIN; PROTOZOAL PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BAGG ALBINO MOUSE; CROSS PROTECTION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; LEISHMANIA; LEISHMANIA MAJOR; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; PARASITE LOAD; PARASITOLOGY; PHYSIOLOGY; SKIN LEISHMANIASIS; VACCINATION;

ANIMALS; CLONING, MOLECULAR; CROSS PROTECTION; CYTOKINES; DISEASE SUSCEPTIBILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, HUMORAL; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PARASITE LOAD; POLYPROTEINS; PROTOZOAN PROTEINS; VACCINATION; VACCINES, DNA;

EID: 84869830706     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-43-59     Document Type: Article

References (87)

1. Leishmaniasis: current situation and new perspectives. Desjeux P, Comp Immunol Microbiol Infect Dis 2004 27 305 318 10.1016/j.cimid.2004.03.004 15225981 (Pubitemid 38842803)
2. Vaccines to combat the neglected tropical diseases. Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, Petri W, Reed S, Valenzuela JG, Hotez PJ, Immunol Rev 2011 239 237 270 10.1111/j.1600-065X.2010.00976.x 21198676
3. Leishmaniasis emergence in Europe. Ready PD, Euro Surveill 2010 15 19505 20403308
4. The aetiological agents of American cutaneous leishmaniasis in the municipality of Monte Negro, Rondonia state, western Amazonia, Brazil. Shaw JJ, De Faria DL, Basano SA, Corbett CE, Rodrigues CJ, Ishikawa EA, Camargo LM, Ann Trop Med Parasitol 2007 101 681 688 10.1179/136485907X229103 18028729 (Pubitemid 350219464)
5. Systemic therapy of New World cutaneous leishmaniasis: a case report and review article. Abadir A, Patel A, Haider S, Can J Infect Dis Med Microbiol 2011 21 79 e83
6. Leishmaniasis emergence and climate change. Ready PD, Rev Sci Tech 2008 27 399 412 18819668
7. Advances in leishmaniasis. Murray HW, Berman JD, Davies CR, Saravia NG, Lancet 2005 366 1561 1577 10.1016/S0140-6736(05)67629-5 16257344 (Pubitemid 41540115)
8. Vaccines and vaccination strategies against human cutaneous leishmaniasis. Okwor I, Uzonna J, Hum Vaccin 2009 5 291 301 10.4161/hv.5.5.7607 19221514
9. Detection of Leishmania parasites in the blood of patients with isolated cutaneous leishmaniasis. Nakkash-Chmaisse H, Makki R, Nahhas G, Knio K, Nuwayri-Salti N, Int J Infect Dis 2011 15 491 e494 10.1016/j.ijid.2011.03.022 21621442
10. Treatment of cutaneous leishmaniasis among travellers. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C, J Antimicrob Chemother 2004 53 158 166 10.1093/jac/dkh058 14729756 (Pubitemid 38239944)
11. Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics. Ameen M, Clin Exp Dermatol 2010 35 699 705 10.1111/j.1365-2230.2010.03851.x 20831602
12. Cutaneous leishmaniasis. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, Lancet Infect Dis 2007 7 581 596 10.1016/S1473-3099(07) 70209-8 17714672 (Pubitemid 47277438)
13. DNA vaccines: immunology, application, and optimization*. Gurunathan S, Klinman DM, Seder RA, Annu Rev Immunol 2000 18 927 974 10.1146/annurev.immunol.18.1.927 10837079 (Pubitemid 30365401)
14. DNA vaccines against protozoan parasites: advances and challenges. Dumonteil E, J Biomed Biotechnol 2007 2007 90520 17710244
15. L-arginine metabolism and its impact on host immunity against Leishmania infection. Wanasen N, Soong L, Immunol Res 2008 41 15 25 10.1007/s12026-007- 8012-y 18040886 (Pubitemid 351903815)
16. Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. Das P, Lahiri A, Chakravortty D, PLoS Pathog 2010 6 1000899 10.1371/journal.ppat. 1000899 20585552
17. The importance of CD11b+dendritic cells in CD4+ T cell activation in vivo: with help from interleukin 1. Iwasaki A, J Exp Med 2003 198 185 190 10.1084/jem.20030737 12860934 (Pubitemid 36987847)
18. Transgenic Leishmania and the immune response to infection. Beattie L, Evans KJ, Kaye PM, Smith DF, Parasite Immunol 2008 30 255 266 10.1111/j.1365-3024.2008.01020.x 18266814 (Pubitemid 351347571)
19. Development of vaccines against visceral leishmaniasis. Evans KJ, Kedzierski L, J Trop Med 2012 2012 892817 21912561
20. During canine viscero-cutaneous leishmaniasis the anti-Hsp70 antibodies are specifically elicited by the parasite protein. Quijada L, Requena JM, Soto M, Alonso C, Parasitology 1996 112 277 284 10.1017/S0031182000065793 8728991 (Pubitemid 26092394)
21. Molecular characterization of a Leishmania donovani infantum antigen identified as histone H2A. Soto M, Requena JM, Gomez LC, Navarrete I, Alonso C, Eur J Biochem 1992 205 211 216 10.1111/j.1432-1033.1992.tb16770.x 1555581
22. Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Soto M, Requena JM, Quijada L, Perez MJ, Nieto CG, Guzman F, Patarroyo ME, Alonso C, Clin Exp Immunol 1999 115 342 349 10.1046/j.1365-2249.1999.00796.x 9933463 (Pubitemid 29052461)
23. Genomic organization and expression of two independent gene arrays coding for two antigenic acidic ribosomal proteins of Leishmania. Soto M, Requena JM, Garcia M, Gomez LC, Navarrete I, Alonso C, J Biol Chem 1993 268 21835 21843 8408038 (Pubitemid 23320685)
24. Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family. MacFarlane J, Blaxter ML, Bishop RP, Miles MA, Kelly JM, Eur J Biochem 1990 190 377 384 10.1111/j.1432-1033.1990.tb15586.x 2163842 (Pubitemid 20201526)
25. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Skeiky YA, Benson DR, Guderian JA, Whittle JA, Bacelar O, Carvalho EM, Reed SG, Infect Immun 1995 63 4105 4114 7558326
26. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Melby PC, Ogden GB, Flores HA, Zhao W, Geldmacher C, Biediger NM, Ahuja SK, Uranga J, Melendez M, Infect Immun 2000 68 5595 5602 10.1128/IAI.68.10. 5595-5602.2000 10992459
27. Leishmania chagasi T-cell antigens identified through a double library screen. Martins DR, Jeronimo SM, Donelson JE, Wilson ME, Infect Immun 2006 74 6940 6948 10.1128/IAI.02032-05 17000724 (Pubitemid 44913169)
28. Immune response regulation by leishmania secreted and nonsecreted antigens. Santarem N, Silvestre R, Tavares J, Silva M, Cabral S, Maciel J, Cordeiro-da-Silva A, J Biomed Biotechnol 2007 2007 85154 17710243
29. Molecular determinants and regulation of Leishmania virulence. Chang KP, McGwire BS, Kinetoplastid Biol Dis 2002 1 1 10.1186/1475-9292-1-1 12234388 (Pubitemid 38751400)
30. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Chang KP, Reed SG, McGwire BS, Soong L, Acta Trop 2003 85 375 390 10.1016/S0001-706X(02)00238-3 12659975 (Pubitemid 36355875)
31. The Leishmania infantum histone H3 possesses an extremely divergent N-terminal domain. Soto M, Requena JM, Morales G, Alonso C, Biochim Biophys Acta 1994 1219 533 535 10.1016/0167-4781(94)90082-5 7918653
32. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Charest H, Matlashewski G, Mol Cell Biol 1994 14 2975 2984 7545921 (Pubitemid 24132711)
33. Mapping of the linear antigenic determinants of the Leishmania infantum hsp70 recognized by leishmaniasis sera. Quijada L, Requena JM, Soto M, Gomez LC, Guzman F, Patarroyo ME, Alonso C, Immunol Lett 1996 52 73 79 10.1016/0165-2478(96)02585-0 8905399 (Pubitemid 26336705)
34. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Iborra S, Soto M, Carrion J, Alonso C, Requena JM, Vaccine 2004 22 3865 3876 10.1016/j.vaccine.2004.04.015 15364433 (Pubitemid 39208748)
35. Challenges and perspectives in vaccination against leishmaniasis. de Oliveira CI, Nascimento IP, Barral A, Soto M, Barral-Netto M, Parasitol Int 2009 58 319 324 10.1016/j.parint.2009.07.013 19698801
36. Vaccine candidates for leishmaniasis: a review. Nagill R, Kaur S, Int Immunopharmacol 2011 11 1464 1488 10.1016/j.intimp.2011.05.008 21616175
37. The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Raab D, Graf M, Notka F, Schodl T, Wagner R, Syst Synth Biol 2010 4 215 225 10.1007/s11693-010-9062-3 21189842
38. GeneArt http://www.invitrogen.com/site/us/en/home/Products-and-Services/ Applications/Cloning/gene-synthesis.html?CID=fl-genesynthesis
39. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Bauer H, Darji A, Chakraborty T, Weiss S, Gene Ther 2005 12 364 372 10.1038/sj.gt.3302423 15616604 (Pubitemid 40310139)
40. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines. Carrion J, Folgueira C, Alonso C, Vaccine 2008 26 1155 1165 10.1016/j.vaccine. 2007.12.051 18255202
41. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. Scott P, Pearce E, Natovitz P, Sher A, J Immunol 1987 139 221 227 3495599 (Pubitemid 17091788)
42. Animal models for the analysis of immune responses to leishmaniasis. Sacks DL, Melby PC, Curr Protoc Immunol 2001 19 19.2
43. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G, J Immunol Methods 1999 223 77 92 10.1016/S0022-1759(98)00204-X 10037236 (Pubitemid 29096240)
44. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. Ding AH, Nathan CF, Stuehr DJ, J Immunol 1988 141 2407 2412 3139757
45. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, Weber V, Soler G, Celada A, Modolell M, Muller I, FASEB J 2005 19 1000 1002 15811879 (Pubitemid 40827731)
46. Infection with arginase-deficient Leishmania major reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis. Muleme HM, Reguera RM, Berard A, Azinwi R, Jia P, Okwor IB, Beverley S, Uzonna JE, J Immunol 2009 183 8068 8076 10.4049/jimmunol.0803979 19923451
47. Determination of arginase activity in macrophages: a micromethod. Corraliza IM, Campo ML, Soler G, Modolell M, J Immunol Methods 1994 174 231 235 10.1016/0022-1759(94)90027-2 8083527 (Pubitemid 24297154)
48. The increase in mannose receptor recycling favors arginase induction and Trypanosoma cruzi survival in macrophages. Garrido VV, Dulgerian LR, Stempin CC, Cerban FM, Int J Biol Sci 2011 7 1257 1272 22110379
49. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F, Antimicrob Agents Chemother 1995 39 2167 2168 10.1128/AAC.39.9.2167 8540741
50. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Scott P, Exp Parasitol 1989 68 369 372 10.1016/0014-4894(89)90120-3 2522884
51. Mechanism and regulation of immunoglobulin isotype switching. Coffman RL, Lebman DA, Rothman P, Adv Immunol 1993 54 229 270 8379463 (Pubitemid 23289254)
52. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major. Chenik M, Louzir H, Ksontini H, Dilou A, Abdmouleh I, Dellagi K, Vaccine 2006 24 2521 2529 10.1016/j.vaccine.2005.12.027 16417957 (Pubitemid 43290382)
53. Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice. Carrion J, Nieto A, Soto M, Alonso C, Microbes Infect 2007 9 735 743 10.1016/j.micinf.2007.02.018 17400015 (Pubitemid 46660686)
54. Mechanisms of immunity to Leishmania major infection in mice: the contribution of DNA vaccines coding for two novel sets of histones (H2A-H2B or H3-H4). Carrion J, Comp Immunol Microbiol Infect Dis 2011 34 381 386 10.1016/j.cimid.2011.06.002 21840052
55. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC, Vaccine 2006 24 1928 1940 10.1016/j.vaccine.2005.10.052 16310897 (Pubitemid 43238276)
56. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Carrion J, Folgueira C, Alonso C, Vaccine 2008 26 2537 2544 10.1016/j.vaccine.2008.03.003 18400342
57. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP, Infect Immun 2003 71 3988 3994 10.1128/IAI.71.7.3988-3994.2003 12819086 (Pubitemid 36753724)
58. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP, Microbes Infect 2007 9 1070 1077 10.1016/j.micinf.2007.05.012 17644455 (Pubitemid 47287743)
59. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Ghosh A, Labrecque S, Matlashewski G, Vaccine 2001 19 3169 3178 10.1016/S0264-410X(01)00023-8 11312013 (Pubitemid 32324046)
60. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Ghosh A, Zhang WW, Matlashewski G, Vaccine 2001 20 59 66 10.1016/S0264-410X(01)00322-X 11567746 (Pubitemid 32905314)
61. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, Luiz Tafuri W, Resende Dde M, Hermont V, Abrantes Cde F, Gazzinelli RT, Vaccine 2008 26 5888 5895 10.1016/j.vaccine.2008.05.095 18786587
62. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells. Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, Resende JM, Pilo-Veloso D, Rezende SA, Bruna-Romero O, Fernandes AP, Gazzinelli RT, Vaccine 2008 26 4585 4593 10.1016/j.vaccine.2008. 05.091 18588933
63. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S, Vaccine 2009 28 53 62 10.1016/j.vaccine.2009.09.114 19818721
64. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. Yam KK, Hugentobler F, Pouliot P, Stern AM, Lalande JD, Matlashewski G, Olivier M, Cousineau B, J Med Microbiol 2011 60 1248 1260 10.1099/jmm.0.029959-0 21527547
65. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L, Vaccine 2007 25 4159 4169 10.1016/j.vaccine.2007.03.006 17395340 (Pubitemid 46635953)
66. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Kaur J, Kaur T, Kaur S, Acta Trop 2011 119 50 56 10.1016/j.actatropica.2011.04.007 21530477
67. Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model. Sachdeva R, Banerjea AC, Malla N, Dubey ML, PLoS One 2009 4 7880 10.1371/journal.pone.0007880 19956549
68. Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice. Kaur T, Sobti RC, Kaur S, Parasite Immunol 2011 33 95 103 10.1111/j.1365-3024.2010.01253.x 21226722
69. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Zhang WW, Charest H, Ghedin E, Matlashewski G, Mol Biochem Parasitol 1996 78 79 90 10.1016/S0166-6851(96)02612-6 8813679 (Pubitemid 26202337)
70. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Zhang WW, Matlashewski G, Proc Natl Acad Sci USA 1997 94 8807 8811 10.1073/pnas.94.16.8807 9238059 (Pubitemid 27335121)
71. Leishmania infection and virulence. Matlashewski G, Med Microbiol Immunol 2001 190 37 42 11770107 (Pubitemid 33079355)
72. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Zhang WW, Matlashewski G, Mol Microbiol 2001 39 935 948 10.1046/j.1365-2958.2001.02286.x 11251814 (Pubitemid 32176338)
73. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. Zhang WW, Mendez S, Ghosh A, Myler P, Ivens A, Clos J, Sacks DL, Matlashewski G, J Biol Chem 2003 278 35508 35515 10.1074/jbc.M305030200 12829719 (Pubitemid 37102322)
74. Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G, Clin Diagn Lab Immunol 1997 4 530 535 9302200 (Pubitemid 27448617)
75. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Srivastava P, Annu Rev Immunol 2002 20 395 425 10.1146/annurev.immunol.20.100301.064801 11861608 (Pubitemid 34293430)
76. Roles of heat-shock proteins in innate and adaptive immunity. Srivastava P, Nat Rev Immunol 2002 2 185 194 10.1038/nri749 11913069 (Pubitemid 37328765)
77. Peptides complexed with the protein HSP70 generate efficient human cytolytic T-lymphocyte responses. Javid B, MacAry PA, Oehlmann W, Singh M, Lehner PJ, Biochem Soc Trans 2004 32 622 625 10.1042/BST0320622 15270691 (Pubitemid 39120399)
78. In vitro reconstitution of heat shock protein-peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases. Li Z, Methods 2004 32 25 28 10.1016/S1046-2023(03)00183-X 14624873 (Pubitemid 37421176)
79. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Hoos A, Levey DL, Expert Rev Vaccines 2003 2 369 379 10.1586/14760584.2.3.369 12903802 (Pubitemid 36713363)
80. Dendritic cells, new tools for vaccination. Colino J, Snapper CM, Microbes Infect 2003 5 311 319 10.1016/S1286-4579(03)00033-9 12706444 (Pubitemid 36428720)
81. Arginase I induction during Leishmania major infection mediates the development of disease. Iniesta V, Carcelen J, Molano I, Peixoto PM, Redondo E, Parra P, Mangas M, Monroy I, Campo ML, Nieto CG, Corraliza I, Infect Immun 2005 73 6085 6090 10.1128/IAI.73.9.6085-6090.2005 16113329 (Pubitemid 41193047)
82. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Agallou M, Margaroni M, Karagouni E, Vaccine 2011 29 5053 5064 10.1016/j.vaccine.2011.04.089 21569815
83. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Wu W, Huang L, Mendez S, Eur J Immunol 2010 40 2517 2527 10.1002/eji.201040484 20683901
84. IL-17 and Th17 Cells. Korn T, Bettelli E, Oukka M, Kuchroo VK, Annu Rev Immunol 2009 27 485 517 10.1146/annurev.immunol.021908.132710 19132915
85. Th17 cells: effector T cells with inflammatory properties. Korn T, Oukka M, Kuchroo V, Bettelli E, Semin Immunol 2007 19 362 371 10.1016/j.smim.2007.10. 007 18035554 (Pubitemid 351274046)
86. The effector T helper cell triade. Fietta P, Delsante G, Riv Biol 2009 102 61 74 19718623
87. Interleukin-17-mediated control of parasitemia in experimental Trypanosoma congolense infection in mice. Mou Z, Jia P, Kuriakose S, Khadem F, Uzonna JE, Infect Immun 2010 78 5271 5279 10.1128/IAI.00168-10 20855512